Résultat(s) 1 - 2 résultats de 2, Temps de recherche: 0,06s Affiner les résultats
  1. 1
    A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

    A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in... par Leijen, S, Soetekouw, P, Jeffry Evans, T, Nicolson, M, Schellens, J, Learoyd, M, Grinsted, L, Zazulina, V, Pwint, T, Middleton, M

    Publié 2011
    Journal article
  2. 2
    A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.

    A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in... par Leijen, S, Soetekouw, P, Jeffry Evans, T, Nicolson, M, Schellens, J, Learoyd, M, Grinsted, L, Zazulina, V, Pwint, T, Middleton, M

    Publié 2011
    Journal article

Outils de recherche: